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ARTICLE
Development of a chimeric Zika vaccine using a
licensed live-attenuated ﬂavivirus vaccine as
backbone
Xiao-Feng Li1,2, Hao-Long Dong1, Hong-Jiang Wang1,3, Xing-Yao Huang1, Ye-Feng Qiu4, Xue Ji1, Qing Ye1,2,
Chunfeng Li1,5, Yang Liu6, Yong-Qiang Deng1, Tao Jiang1, Gong Cheng6, Fu-Chun Zhang2, Andrew D. Davidson7,
Ya-Jun Song 1, Pei-Yong Shi8,9 & Cheng-Feng Qin 1,2
The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects
necessitates the rapid development of a safe and effective vaccine. Here we report the
development and characterization of a recombinant chimeric ZIKV vaccine candidate
(termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese
encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its
replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in
multiple animal models. Remarkably, immunization of mice and rhesus macaques with a
single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers
complete protection against ZIKV challenge. Signiﬁcantly, female mice immunized with
ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during
pregnancy. Overall, our study provides an alternative vaccine platform in response to the
ZIKV emergency, and the safety, immunogenicity, and protection proﬁles of ChinZIKV
warrant further clinical development.
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Zika virus (ZIKV) is a mosquito-borne virus belonging tothe Flavivirus genus of the Flaviviridae family, whichincludes other important human pathogens such as yellow
fever virus (YFV), dengue virus (DENV), Japanese encephalitis
virus (JEV), West Nile virus (WNV), and tick-borne encephalitis
virus (TBEV). Since 2007, ZIKV has caused epidemics in Poly-
nesia, in the South Paciﬁc, and most recently in the United States.
Increasing evidence supports a casual association between ZIKV
infection, microcephaly, and other congenital malformations in
infants, as well as Guillain–Barré syndrome in adults1–3. In
addition, unlike most other ﬂavivirus members, ZIKV has the
potential for signiﬁcant human-to-human transmission through
sexual and vertical routes3,4. These unexpected and unique
properties underscore the urgent requirement for the develop-
ment of a safe and effective ZIKV vaccine. The existence of a
number of successful ﬂavivirus vaccines and multiple vaccine
development platforms, has facilitated remarkable progress in the
ﬁeld of ZIKV vaccine development. Recently, a range of non-
replicating ZIKV vaccine candidates including; DNA vaccines
expressing the viral prM-E genes, puriﬁed inactivated vaccines,
and messenger RNA vaccines have been developed and evaluated
in animals with promising results5–10, and some have now
entered clinical trials11,12.
The immune mechanisms that mediate protection against
ZIKV infection are not fully understood. In comparison with
non-replicating vaccines, live-attenuated vaccines are designed to
mimic the natural life cycle of the wild-type virus and are capable
of inducing long-lasting immune responses with low production
cost. These characteristics make live-attenuated vaccines the most
effective countermeasure against many viral diseases, as exem-
pliﬁed by the two ﬂavivirus vaccines, YFV vaccine strain 17D
(YFV 17D), and JE vaccine virus SA14-14-2 (JEV SA14-14-2).
Both vaccines are recognized for their excellent safety and efﬁcacy
proﬁles in humans. Neutralizing antibodies targeting ﬂavivirus
structural proteins prevent or reduce viral replication, leading to
the clearance of extracellular viruses and commonly correlate
with protection from disease. For example, neutralizing antibody
titers (> 10), which correlate with protective efﬁcacy, have been
reported for ﬂavivirus vaccines including YFV, JEV, and TBEV13–
15. CD8+ T cells limit the spread of viruses by either recognizing
and killing infected cells or secreting speciﬁc antiviral cytokines,
whereas CD4+ T cells contribute to protection through cytokine
production and support the generation and maintenance of
antibody and CD8+ T-cell responses. Multiple studies have sug-
gested that the T-cell response is a critical contributor to pro-
tective immunity in ﬂavivirus infections16–18. Recently, two live-
attenuated ZIKV vaccine candidates have been generated by
reverse genetics and shown capable of inducing sterilizing
immunity in animal models10,19,20.
Flaviviruses have an 11 kb single-stranded positive-sense RNA
genome that contains a single open reading frame (ORF) ﬂanked
by two untranslated regions (5′- and 3′-UTRs). The ORF encodes
a single polyprotein, which is proteolytically processed into three
structural proteins (C, prM, and E) and seven nonstructural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). One
platform for the development of ﬂavivirus vaccine candidates has
been the creation of a recombinant chimeric ﬂavivirus in which
the prM and E genes of a live-attenuated ﬂavivirus vaccine strain
are substituted with the corresponding genes of a heterologous
ﬂavivirus21. Recombinant live-attenuated chimeric DENV (CYD-
TDV) and JEV vaccines, using YFV 17D as a backbone, have been
well characterized in terms of immunogenicity and safety, and are
now commercially available in several countries22,23. Several
other chimeric vaccines based on different attenuated strains are
currently under different stages of development24,25. The live-
attenuated JEV vaccine virus SA14-14-2, recently prequaliﬁed by
the World Health Organization (WHO), has been administered
to more than 400 million children26. Large-scale vaccination
programs in various countries have shown that the vaccine pos-
sesses an excellent safety proﬁle and remarkable effectiveness and
efﬁcacy27–29. The phenotypic and genotypic characteristics that
correlate with attenuation are highly stable26. These attractive
features of JEV SA14-14-2 make it an ideal genetic backbone for
the development of chimeric ﬂavivirus vaccines30.
In the present study, we develop a chimeric live-attenuated
ZIKV vaccine candidate, using JEV SA14-14-2 as a backbone, and
through extensive in vitro and in vivo characterization demon-
strate that the chimeric virus is a promising ZIKV vaccine can-
didate, which deserves further clinical development.
Results
Construction and characterization of ChinZIKV. Using stan-
dard reverse genetics technology, we rationally designed and
generated a JEV-ZIKV chimera (named ChinZIKV) by replace-
ment of the prM-E genes of JEV SA14-14-2 with the corre-
sponding region of an Asian ZIKV strain FSS1302531 (Fig. 1a).
The resulting chimeric virus, ChinZIKV, was successfully con-
structed and rescued in BHK-21 cells and conﬁrmed by full
genome sequencing. Accordingly, the chimera expressed the
structural proteins of ZIKV and the non-structural proteins of
JEV as veriﬁed by immunostaining (Fig. 1b and Supplementary
Fig. 1a) and western blotting (Supplementary Fig. 1b), respec-
tively. ChinZIKV caused cytopathic effects (CPE) at low multi-
plicities of infection and exhibited a small-plaque phenotype in
BHK-21 cells, which is a potential attenuation marker, compared
with the parental ZIKV (Fig. 1c). Similar to other ﬂaviviruses,
ChinZIKV replicated efﬁciently in both mammalian and mos-
quito cells, with a peak titer of 106 PFUml–1 in Vero cells, which
is a certiﬁed cell type for vaccine production by the WHO (Fig. 1d
and Supplementary Fig. 1c).
Genetic stability is one of essential properties required of a
potent live-attenuated vaccine. To test this, we serially passaged
ChinZIKV in Vero cells six times. Full-genome sequence analysis
of the 6th passaged virus (P6) revealed a total of six nucleotide
mutations, resulting in single amino acid substitutions in the prM
and NS1 proteins, which accumulated during the serial passages
(Supplementary Table 1), possibly related to adaptation to Vero
cells. Phenotypic comparison showed no apparent change in
plaque morphology at different passages (Fig. 1c and Supple-
mentary Fig. 1c) and the P6 virus showed more efﬁcient
replication in Vero cells compared with the P0 virus (Fig. 1d
and Supplementary Fig. 1d).
Characterization of the attenuation phenotype of ChinZIKV.
The in vitro properties of ChinZIKV encouraged us to test the
attenuation phenotype in vivo. We ﬁrst examined the viremia and
tissue distribution of ChinZIKV in the well-established immu-
nodeﬁcient A129 mouse model32. Although no statistically sig-
niﬁcant difference was observed between the body weights of
mice infected with ChinZIKV or ZIKV up to 15 days post
infection (Supplementary Fig. 2c), ChinZIKV showed a sig-
niﬁcant attenuation phenotype in comparison with the wild-type
ZIKV, with a much weaker viremia proﬁle (Fig. 2a), as well as
decreased viral loads in spleens and testis (Supplementary Fig. 2a,
b). In addition, the A129 mice were not found to be persistently
infected with ChinZIKV, as evidenced by undetectable levels of
viral RNA in the organs of infected mice at day 15 post infection
(Supplementary Fig. 2d). Then, we inoculated immunocompetent
BALB/c mice with ChinZIKV and wild-type ZIKV by the intra-
peritoneal (i.p.) route7,33. Consistent with the results obtained
using the A129 mice, there was no signiﬁcant difference in the
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body weights of mice inoculated with ChinZIKV or ZIKV
(Supplementary Fig. 3a). Remarkably, barely detectable viremia
was observed in the ChinZIKV-infected mice, whereas ZIKV
infection induced a rapid and transient viremia in mice (Fig. 2b).
Viral RNA was barely detectable in the spleens and testis of
ChinZIKV-inoculated mice (Supplementary Fig. 3b, c).
We also tested the neurovirulence of ChinZIKV in 1-day-old
suckling BALB/c mice following intracerebral (i.c.) inoculation, in
comparison with the same doses of wild type ZIKV and the two
licensed live-attenuated vaccines YFV 17D and JEV SA14-14-2.
As shown in Supplementary Fig. 4, all suckling mice succumbed
to i.c. inoculation with wild-type ZIKV within 20 days, whereas
no death or neurological signs were observed in all ChinZIKV-
inoculated mice during the observation period. As expected, the
two live-attenuated vaccine viruses were neurovirulent and all
animals died between days 7–9 post inoculation with either JEV
SA14-14-2 or YFV 17D (Supplementary Fig. 4). These ﬁndings
demonstrate that ChinZIKV has a signiﬁcantly less neurovirulent
phenotype than ZIKV as well as the two licensed ﬂavivirus
vaccine viruses.
Ideally, a live-attenuated vaccine candidate should lose the
capability to be transmitted by vector mosquitoes. To characterize
the infectivity of ChinZIKV in Aedes aegypti, equal doses of
ChinZIKV and wild-type ZIKV were microinjected into the
thorax of mosquitoes, and viral replication assayed on day 6 post
inoculation. As shown in Supplementary Fig. 5, high levels of
ZIKV RNA were detected in all tested mosquitoes, whereas only
trace amounts of viral RNA were detected in ChinZIKV-
inoculated mosquitoes at the same time. These data suggest
almost undetectable replication of ChinZIKV in A. aegypti
mosquitoes.
A non-human primate model for ZIKV infection, capable of
developing measurable viremia and neutralizing cellular immune
responses, has been well established by us and other groups34–36
as an indicator for vaccine safety and efﬁcacy in humans. Using
our rhesus macaque model, we compared the replication of
ChinZIKV with the ZIKV epidemic strain GZ0135. Monkeys
(n = 3) infected subcutaneously (s.c.) with 105 PFU of ZIKV strain
GZ01, all developed sustained viremia within 10 days post
infection, whereas monkeys (n = 5) infected with 105 PFU of
ChinZIKV failed to exhibit any detectable viremia (Fig. 2c). In
addition, viral RNA was readily detected in the urine and saliva of
ZIKV-infected monkeys, but not ChinZIKV-inoculated monkeys
(Fig. 2d, e). Together, the attenuation phenotype of ChinZIKV in
mice and non-human primates was comparable or superior to
previous licensed live-attenuated YFV, JEV, or chimeric DENV
vaccines21,37,38.
ZIKV-speciﬁc immune responses induced by ChinZIKV in
animals. Next, we investigated the immunogenicity proﬁle of
ChinZIKV in mice and non-human primates. ZIKV contains
only one serotype39 and a neutralization antibody threshold of >
1 : 10 is considered protective against ﬂavivirus infection13,14.
A single s.c. immunization of adult BALB/c mice with ChinZIKV
induced high levels of both ZIKV-speciﬁc IgG and neutralizing
antibodies on day 28 post immunization (Supplementary Fig. 6).
Importantly, anti-ZIKV neutralizing antibodies (Geometric mean
titer (GMT) = 26) were detected in all ChinZIKV-immunized
mice, even at day 210 post immunization (Supplementary Fig. 6).
Rhesus monkeys (n = 5) were then immunized with ChinZIKV
by the s.c. route. High levels of ZIKV-speciﬁc IgG (GMT = 3,675)
and neutralizing antibodies (GMT = 76) were detected on day 28
post immunization (Fig. 3a, b). No ZIKV-speciﬁc antibodies were
detected in phosphate buffered solution (PBS)-immunized
animals (n = 3), as expected. Although the precise role of the T-
cell response during ZIKV infection remains largely
unknown40,41, T-cell responses to the ﬂavivirus E protein have
been associated with protection in humans42. enzyme-linked
immunosorbent spot (ELISPOT) assay showed that ZIKV E-
speciﬁc interferon-γ (IFN-γ) secretion was signiﬁcantly induced
in peripheral blood mononuclear cells (PBMC) from ChinZIKV-
immunized monkeys on day 8 post immunization (Fig. 3c). Other
modest cellular immune responses, including the induction of
interleukin (IL)-2 and IL-10, were also observed in ChinZIKV-
immunized monkeys (Supplementary Fig. 7a, b), suggesting both
Th1 and Th2 responses were elicited. In addition, Luminex bead
assays showed a similar, but slightly weaker, pattern of cytokine
induction in ChinZIKV-immunized monkeys compared with that
found in natural ZIKV infection (Fig. 3d). Multiple cytokines
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Fig. 1 Construction and characterization of ChinZIKV. a Strategy for
construction of the chimeric ZIKV vaccine ChinZIKV and schematic
representation of its genome. b Immunostaining of BHK-21 cells infected
with ChinZIKV-, ZIKV-, or mock-infected at an MOI of 0.01 at 48 h post-
infection with ZIKV patient anti-serum and JEV NS1 antibodies. Scale bar:
100 μm. c Plaque morphology of ZIKV, the recovered ChinZIKV, and
ChinZIKV at passages 3 and 6 on BHK-21 cells. BHK-21 cells were infected
with the indicated viruses, and plaques were developed after 96 h. d
Growth curves of the recovered ChinZIKV and ChinZIKV at passage 6 in
Vero cells. Vero cells were infected with the indicated viruses at an MOI of
2 and the cell supernatants were collected at the indicated times for
determination of virus titers by plaque assay using BHK-21 cells. The data
are representative of at least three independent experiments and error bars
indicate the SD
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with adaptive immunomodulatory roles, including IL-1b, IFN-γ,
monocyte chemotactic protein 1 (MCP-1), macrophage migration
inhibitory factor (MIF), macrophage inﬂammatory protein 1b
(MIP-1b), IL-8, and IFN-gamma-inducible protein 10 (IP-10),
were concurrently elevated upon either ZIKV infection or
ChinZIKV immunization. These data demonstrate that Chin-
ZIKV infection is capable of inducing humoral and cellular
immune responses in mice and non-human primates that are
similar to those raised by natural ZIKV infection.
Efﬁcacy of ChinZIKV in mice and non-human primates. The
induction of a robust neutralizing antibody response to Chin-
ZIKV in animals led us to explore the protection afforded against
challenge with a contemporary 2016 Venezuelan ZIKV strain43.
We ﬁrst examined the protective effect of ChinZIKV immuni-
zation using immunocompetent BALB/c mice. As expected, all
BALB/c mice immunized with PBS developed a transient viremia
upon s.c. challenge. Remarkably, none of the mice immunized
with a single dose of ChinZIKV exhibited detectable viremia
(Fig. 4a). We further tested whether ChinZIKV immunization
protected pregnant mice and their offspring from ZIKV chal-
lenge. Supporting the previous experiment, viremia was not
observed in the ChinZIKV-immunized pregnant mice following
s.c. challenge with ZIKV (Fig. 4b). More importantly, the off-
spring born to ChinZIKV-immunized dams remained healthy
after i.c. challenge with ZIKV and all littermates grew up without
any neurological symptoms (Fig. 4b). In contrast, all offspring
born to PBS-immunized dams died and had severe neurological
symptoms, including hind limb weakness and paralysis, after i.c.
challenge with ZIKV, as previously described (Fig. 4b)44,45. These
results demonstrate that a single immunization with ChinZIKV
confers protection of both pregnant dams and their offspring
against wild type ZIKV challenge.
Furthermore, we tested the protective efﬁcacy of ChinZIKV in
a rhesus macaque monkey model. As shown in Fig. 4c, challenge
of all PBS-immunized animals with wild-type ZIKV led to
sustained viremia within 10 days post infection. Remarkably,
monkeys immunized with a single dose of ChinZIKV were
completely protected against ZIKV challenge, as evidenced by the
lack of detectable viremia observed during the post-challenge
period (Fig. 4c). In addition, Luminex bead assay showed that
multiple cytokines were signiﬁcantly elevated in the sera of PBS-
immunized monkeys in comparison with ChinZIKV-immunized
monkeys, upon ZIKV challenge (Supplementary Fig. 8a). Speci-
ﬁcally, the levels of disease-related cytokines including IFN-γ,
MIF, and MCP-1 were signiﬁcantly lower in the sera of
ChinZIKV-immunized monkeys compared with the control
group (Fig. 4d). The levels of multiple cytokines including IL-2,
IL-Ra, RANTES (regulated on activation, normal T cell expressed
and secreted; CCL-5), and eotaxin showed a divergent proﬁle
between ChinZIKV-immunized and PBS-inoculated animals
following ZIKV challenge (Supplementary Fig. 8b), which may
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Fig. 2 ChinZIKV is highly attenuated in mice and non-human primates. a, b Viral load in serum in mice inoculated with ChinZIKV or ZIKV. Four-week-old
male mice were infected with 103 (A129) or 105 PFU (BALB/c) of the indicated viruses by the s.c. or i.p. routes, respectively. Viral RNA loads were
determined by reverse transcription-quantitative PCR (RT-qPCR). Dotted lines indicate the detection limit. The data are representative of at least three
independent experiments, and error bars indicate the SD. Signiﬁcance was calculated using a two-way ANOVA with multiple comparison tests a, b (**P-
value< 0.01; ****P-value< 0.0001). Viral load in serum c, urine d, and saliva e of monkeys infected with ChinZIKV or ZIKV. Monkeys were infected with
105 PFU of ChinZIKV or ZIKV by the s.c. route. Blood and tested ﬂuids were collected at the indicated times. Viral RNA amounts in the tested samples were
determined by RT-qPCR
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contribute to the protection against ﬂavivirus challenge46. The
potent proinﬂammatory and T-cell responses, together with the
production of high-titer-neutralizing antibodies, are likely to
jointly contribute to the protection in the non-human primates.
ChinZIKV prevents vertical transmission and fetus damage.
Finally, to further test the ability of ChinZIKV immunization to
prevent vertical ZIKV transmission during pregnancy15,47, we
mated immunized BALB/c female mice with 10-week-old naive
BALB/c male mice at day 210 post immunization. Pregnant dams
were then administered 2.0 mg of anti-Ifnar1 blocking antibody at
embryo day 5 (E5) and 1 day later (E6), challenged with 105 PFU
of ZIKV. Viral RNA loads in serum were determined at days
1–3 post challenge by RT-qPCR. At E13, animals were killed, and
maternal tissues were collected and viral RNA levels quantiﬁed
(Fig. 5a). As expected, following ZIKV challenge, ChinZIKV-
immunized dams had no detectable viremia during the observa-
tion period, whereas PBS-immunized mice sustained high levels
of viremia at the indicated time points (Fig. 5b). Consistent with
this observation, high levels of viral RNA were detected in
maternal spleens and brains in PBS-immunized mice, whereas no
detectable viral RNA was observed in ChinZIKV-immunized
mice (Fig. 5c). More importantly, viral RNA was not detectable in
placentas and fetal heads from the ChinZIKV-immunized dams
(Fig. 5d, e). In contrast, high levels of viral RNA were detected in
the corresponding tissues from PBS-immunized dams (Fig. 5d, e).
In addition, extensive placental injury and fetal demise were
observed in PBS-immunized mice at E18, whereas all pups were
delivered at term with normal viability from the ChinZIKV-
immunized group (Fig. 5f, g). These results demonstrate that pre-
conception maternal immunity induced by ChinZIKV immuni-
zation efﬁciently prevented vertical ZIKV transmission during
pregnancy and protected the fetuses from ZIKV infection.
Discussion
In the present study, we rationally engineered a chimeric ZIKV
vaccine candidate by replacement of the prM-E genes of the
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commercial JE vaccine strain SA14-14-2 with the corresponding
segment of ZIKV. As expected, the resulting chimeric ChinZIKV
showed a signiﬁcantly attenuated phenotype in multiple animal
models. ChinZIKV is highly attenuated in mouse neurovirulence,
even more strongly than the two commercial ﬂavivirus live-
attenuated vaccine strains JEV SA14-14-2 and YFV 17D (Sup-
plementary Fig. 4). Recently, we have identiﬁed the major mouse
neurovirulence determinant in the prM protein, which is closely
linked to neurotropism and severe microcephaly in the fetus48.
However, the chimeric ChinZIKV did not contain this virulence
determinant, which further supports its safety proﬁle. Sig-
niﬁcantly, immunocompetent mice and non-human primates
inoculated s.c. with ChinZIKV did not exhibit detectable viremia
(Fig. 2). This unique feature has been reported for other chimeric
live-attenuated ﬂaviviruses, including DENV, WNV, and TBEV,
which have all been developed based on the JEV vaccine strain
SA14-14-230,47,49. We speculate that this difference to YFV-based
chimeric vaccines may be attributed to the intrinsic character-
istics of the JEV SA14-14-2 genetic backbone. Previous investi-
gations have demonstrated that the JEV vaccine SA14-14-2 or
other live-attenuated JEV vaccine candidates did not cause
detectable viremia in mice or monkeys50,51. The underlying
mechanisms accounting for the absence of vaccine viremia
remain elusive and warrant further investigation.
Remarkably, immunization of mice and non-human primates
with a single dose of ChinZIKV elicited a rapid and robust
antibody response, conferring complete protection upon chal-
lenge with an epidemic ZIKV strain. Several non-replicating
ZIKV vaccine candidates have been shown to induce high titers of
neutralizing antibodies that contribute to the solid protective
immunity in animals7–9,52. It is noteworthy that ChinZIKV seems
to induce a higher level of neutralizing antibodies than an equal
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dose of wild type ZIKV in our monkey model (GMT of 76
for ChinZIKV on day 28 p.i. vs GMT of 30 for ZIKV on day
21 p.i.)35, which is probably associated with the higher replication
rate of the JEV backbone. Recently, a vertical ZIKV transmission
model has been used to evaluate the protective efﬁcacy of ZIKV
vaccine candidates8. In our study, a single dose of ChinZIKV can
induce high levels of neutralizing antibodies against ZIKV and
provide a complete prevention of vertical transmission to the
fetus during pregnancy, even as late as day 210 post immuniza-
tion. Similarly, several other vaccine candidates under develop-
ment also prevented vertical transmission of ZIKV across the
placental barrier, thus limiting fetal infection10,19. Collectively,
these results from animal models suggest pre-conception mater-
nal immunity is sufﬁcient to protect against fetal transmission.
Recent data have demonstrated that the cellular immune
response, especially CD8+ T cells, also contributes to protection
against ZIKV infection40,53. Our study showed that ChinZIKV
inoculation was able to elicit obvious secretion of IFN-γ from
PMBCs isolated from monkeys upon stimulation with the ZIKV
E protein. Both ChinZIKV and ZIKV infections also resulted in
similar patterns of cytokine induction, with a slight weaker
induction for ChinZIKV. Notably, the increased secretion of the
chemokines MCP-1, involved in monocyte inﬁltration and IP-10,
involved in the recruitment of activated effector T cells were
observed in both groups. Notably, increased levels of IP-10 and
MCP-1 have been found in ZIKV-infected monkeys and pregnant
women with neonatal microcephaly54–56. These ﬁndings
demonstrate the ChinZIKV chimera is able to induce a similar
cellular immune response proﬁle to that of ZIKV. Interestingly,
following ZIKV challenge, the levels of IFN-γ, MIF, and MCP-1
were signiﬁcantly lower in the ChinZIKV-immunized animals
than that in the PBS control group. MIF has a broad range of
immune and pro-inﬂammatory activities, and has been reported
to be correlated with the severity of dengue disease57,58. MCP-1 is
a potent chemotactic factor for monocytes and macrophages, and
higher MCP-1 levels in placebo recipients than CYD-TDV reci-
pients have been reported59. Reduction in the levels of these
disease related cytokines indicates that immunization with the
chimera confers a strong protective immune response against
ZIKV infection in monkeys. On the other hand, the induction of
a number of cytokines, including IL-2, IL-Ra, RANTES (CCL-5),
and eotaxin diverged markedly between the ChinZIKV-
immunized and PBS-inoculated animals after ZIKV challenge.
It has been reported that chemokine receptor CCR5 functioned as
a key factor in viral clearance and survival in a mouse model of
WNV encephalitis and WNV infection in humans60,61. Increased
production of CCR5 in immunized-monkeys following ZIKV
challenge might contribute to recovery from ZIKV infection.
Although several vaccine candidates have been trialed clini-
cally11, the complexity of ZIKV immunity and pathogenesis has
introduced uncertainty to ZIKV vaccine development62,63. In
particular, recent reports that DENV antibodies can either neu-
tralize or enhance ZIKV infection8 have brought additional levels
of complexity to efforts to develop a safe and effective ZIKV
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vaccine. Live-attenuated vaccines, including the chimeric vaccine
described here, that mimic the kind of protective immunity
induced in people who survive natural ZIKV infection could be a
rational approach to success. A recombinant live-attenuated
ZIKV vaccine candidate has been generated by deletion of 10-nts
in the viral 3′-UTR by reverse genetics, and a single dose
immunization of mice and non-human primates conferred full
protection against ZIKV challenge10,20. The recombinant Chin-
ZIKV developed here is based on a licensed human vaccine, and
can be easily and economically produced on a large-scale using a
similar manufacturing and quality control system, providing a
practical solution for resource-limited areas where ZIKV is
endemic. However, considerable work is still needed to better
deﬁne the biology of ZIKV in humans and in the design and
analysis of clinical trials.
Overall, our preclinical results described here illustrate a safe,
affordable, and effective recombinant chimeric ZIKV vaccine that
deserves further clinical development in the near future. Our data
on the cytokine production patterns following virus immuniza-
tion and challenge represent valuable resources for further study
of the mechanisms underlying protective immunity conferred by
ChinZIKV, as well as other versions of live-attenuated vaccine
candidates against ZIKV.
Methods
Cells and viruses. BHK-21 (baby hamster kidney, ATCC CCL-10) and Vero
(African green monkey kidney, ATCC CCL-81) cells were maintained in Dul-
becco’s minimal essential medium (DMEM; Thermo Fisher Scientiﬁc, USA) sup-
plemented with 10% fetal bovine serum (FBS) and penicillin (100 U
ml–1)–streptomycin (100 μg ml–1). Aedes albopictus C6/36 cells were cultured in
RPMI 1640 supplemented with non-essential amino acids (Thermo Fisher Scien-
tiﬁc) and 10% FBS. BHK-21 and Vero cell lines were grown at 37 °C in 5% CO2,
whereas C6/36 cells were maintained at 28 °C. ZIKV strain GZ01 (GenBank
accession no. KU820898) was originally isolated from the urine sample of a ZIKV
patient returning from Venezuela to China in 201643. ZIKV strain FSS13025
(GenBank accession number KU955593) was originally isolated from Cambodia in
2010 and recovered from an infectious clone of ZIKV31. The JEV vaccine strain
SA14-14-2 and YFV vaccine strain 17D were from the Chengdu Institute of Bio-
logical Products and Beijing Institute of Biological Products, respectively. Virus
titers were determined by standard plaque assay on BHK-21 cells, and virus stocks
were stored in aliquots at − 80 °C until use.
Genetic construction of the JEV/ZIKV chimera. All plasmids were constructed
using standard molecular biology protocols and conﬁrmed by enzyme digestion
and DNA sequencing. Genetic construction of the full-length infectious clone of
JEV has been previously described30,49,64. Cloning sites were engineered to permit
replacement of the entire prM and E coding sequences of JEV with the corre-
sponding sequences of the ZIKV strain FSS13025. The resulting plasmid contained
the full-length complementary DNA of the JEV/ZIKV chimera (named pChin-
ZIKV). Further details about the construction of pChinZIKV are available from the
authors on request and the corresponding primers used in this study are listed in
Supplementary Table 2.
Transcription and transfection. The plasmid pChinZIKV was linearized with
XhoI and used as a template for SP6 RNA polymerase transcription in the presence
of an m7GpppA cap analog. In vitro transcription was done using the RiboMAX
Large Scale Production System (Promega, USA) according to the manufacturer’s
protocol. The yield and integrity of RNA transcripts was analyzed by gel electro-
phoresis under non-denaturing conditions. RNA transcripts (5 μg) were transfected
with Lipofectamine 3000 (Thermo Fisher Scientiﬁc) into BHK-21 cells grown in 60
mm-diameter culture dishes. Supernatants were then collected at day 4 post
transfection, when typical CPE were observed. Virus titers were determined by
standard plaque assay on BHK-21 cells. Brieﬂy, BHK-21 cells in 12-well plates were
infected with a 10-fold serial dilution of viruses. The plates were incubated at 37 °C
for 1 h and cells were overlaid with 1% low-melting point agarose (Promega) in
DMEM containing 2% FBS. After further incubation at 37 °C for 4 days, the cells
were ﬁxed with 4% formaldehyde and stained with 0.2% crystal violet to visualize
the plaques.
Nucleotide sequencing. Viral RNA was isolated using a PureLink RNA minikit
(Thermo Fisher Scientiﬁc) and genomic cDNA was obtained by RT using Super-
Script III (Thermo Fisher Scientiﬁc). For determination of viral consensus
sequences, PCR products were directly sequenced in both directions using virus-
speciﬁc primers. Sequence fragments were assembled into a consensus sequence
with DNA STAR software, version 7.0.
Growth curves. Growth curves of ChinZIKV in BHK-21, C6/36, or Vero cells were
performed in a 12-well plate at a multiplicity of infection (MOI) of 0.01 or 2. Cell
supernatants were collected at successive 12 or 24 h intervals post infection. Viral
titers were then quantitated by plaque assay on BHK-21 cells or by RT-qPCR as
described below.
Immunostaining assay. Immunostaining of ZIKV-infected cells were performed
as previously described43. Brieﬂy, conﬂuent BHK-21 cells grown in six-well plates
containing a 1 cm2 coverslip were infected with viruses at an MOI of 0.01. At 48 h
post infection, the coverslips containing infected cells were removed and directly
used for subsequent analysis. The cells on the coverslip were ﬁxed with ice-cold
acetone and incubated with convalescent sera from a ZIKV patient43 (1 : 200
dilution), a mouse monoclonal antibody against the E protein of ZIKV (1 : 1,000,
Cat#BF-1176-56, BioFront Technologies, USA) or a mouse monoclonal antibody
against the JEV NS1 protein (1 : 20, Cat#ab41651, Abcam, UK) at 37 °C for 1 h. The
use of human sera was approved by the Institutional Review Board of Guangzhou
Eighth People’s Hospital with written informed consent form the patient. Cells
were washed three times with PBS and then incubated with secondary antibodies
conjugated to Alexa Fluor 488 (anti-mouse IgG, 1 : 2,000, Cat#A-11059; anti-
human IgG, 1 : 500, Cat#A-11059, Thermo Fisher Scientiﬁc) in PBS for 30 min at
37 °C. Fluorescent cells were examined using a ﬂuorescence microscope (Olympus,
Japan).
Western blotting assay. Conﬂuent C6/36 cells grown in a six-well plate were
infected with viruses at an MOI of 0.1 or mock infected as control. At 72 h post
infection, cell lysates were mixed with loading buffer (0.1 M Tris-HCl (pH 8.8),
20% glycerol, 1% dithiothreitol, and 3% SDS and 0.0025% bromophenol blue),
heated for 5 min at 100 °C, cooled on ice, and run on a precast 12% SDS-
polyacrylamide gel electrophoresisgel (Biorad, USA). Protein was transferred to
polyvinylidene diﬂuoride membranes and the membranes were blocked overnight
at 4 °C in PBST (Dulbecco’s PBS + 0.2% V/V Tween 20 + 1% bovine serum albu-
min). Following overnight blocking, the membranes were incubated for 1 h at room
temperature with PBST containing a mouse anti-ZIKV E antibody (1 : 1,000,
Cat#BF-1176-56, BioFront Technologies). Membranes were then washed three
times with PBST and incubated for 1 h at RT with PBST containing a 1 : 1,000
dilution of sheep anti-mouse horseradish peroxidase (HRP). Membranes were then
washed three times with PBST and developed using a Pierce ECL western blotting
substrate (Cat#32109, Thermo Fisher Scientiﬁc) according to the manufacturer’s
recommendation.
Genetic stability assay. The recovered virus ChinZIKV was consecutively pas-
saged in Vero cells for six passages. The complete genome sequence, growth curve,
and plaque phenotype of the passaged viruses (P3 or P6) were assessed as described
above. The sixth passage virus (P6) was titered and prepared as a stock for further
in vivo studies.
Enzyme-linked immunosorbent assay. Enzyme-linked immunosorbent assay
(ELISA) was used to determine the IgG antibody titers in the sera of animals.
Brieﬂy, 96-well plates were coated overnight at 4 °C with 1 mgml–1 of recombinant
ZIKV E protein65 in a pH 9.6 carbonate buffer. Subsequently, the coated plates
were incubated with serial dilutions of serum collected from the immunized ani-
mals. After incubation with peroxidase-conjugated goat anti-mouse IgG (1 : 5,000)
(KPL, USA) for 1 h, the plates were then incubated with 3,3’,5,5’-tetra-
mehylbenzidine substrate (Promega). The reaction was stopped by the addition of
2 N H2SO4 to the medium and the absorbance (450 nm) was read using a
microplate reader (Beckman, USA). ELISA endpoint titers were deﬁned as the
highest reciprocal serum dilution that yielded an absorbance > 2-fold over back-
ground values.
Neutralization assay. Neutralizing antibody titers were determined by a standard
50% plaque reduction neutralization test (PRNT50). Brieﬂy, a 1 : 10 dilution of
serum was prepared in DMEM containing 2% FBS and then heat inactivated for 30
min at 56 °C. Serial two- or fourfold dilutions of inactivated serum were mixed with
equal volumes of viral solution to yield a mixture containing ~ 250 PFU of virus per
ml. After incubation at 37 °C for 1 h, 200 μl volumes of the virus–antibody mixtures
were added to wells of 12-well plates containing conﬂuent monolayers of BHK-21
cells. Viral titers were then determined using the plaque assay described above. The
endpoint neutralization titer was calculated by the method of Spearman–Karber66.
Enzyme-linked immunosorbent spot. Cellular immune responses elicited from
PBMCs of monkeys were assessed using the IFN-γ, IL-2 or IL-10 ELISPOT human
set (Abcam) according to the manufacturer’s protocol. Brieﬂy, PBMCs collected
from the immunized or challenged rhesus monkeys were thawed and washed with
Hanks balanced salt solution (HBSS). The cells were then centrifuged at room
temperature at 2,500 r.p.m. for 15 min without braking, followed by two washes
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with HBSS. Then, the cells were re-suspended in RPMI 1640 containing 10% FBS
and diluted to a working concentration of 5 × 106 cells per ml. For ELISPOT
analysis, 0.5 or 0.1 million cells per well were seeded and stimulated with
recombiant ZIKV E protein prepared in our lab65 in 96-well tissue culture dishes
coated with 5 mgml–1 of IFN-γ, IL-2, or IL-10 capture monoclonal antibody. Non-
stimulated and PMA (Merck, Germany)-stimulated cells were used as negative and
positive controls, respectively. The cells were then cultured for 20 h at 37 °C and 5%
CO2. Plates were washed and biotinylated anti-human IFN-γ, IL-2, or IL-10
antibody was added to each well and incubated for 2 h at room temperature.
Thereafter, the plates were washed and incubated for 1 h at room temperature with
streptavidin–HRP. Finally, AEC substrate solution (Abcam) was added and spots
were counted with an ELISPOT Analysis System (At-Spot-2100, China). Assay
results are expressed as the value obtained by the following: (number of spots in
experimental well-number of spots in medium control)/106 cells.
Ethical statement. Research involving animals was approved by and carried out in
strict accordance with the guidelines of the Institutional Experimental Animal
Welfare and Ethics Committee (IACUC-13-2016-001).
Mouse studies. BALB/c and A129 mice used in this study were purchased from
Animal Laboratory Animal Center, Academy of Military Medical Science.
For attenuation tests, groups of 4-week-old male BALB/c or A129 mice were
inoculated by the s.c. or i.p. route with the indicated doses of ChinZIKV or ZIKV,
respectively. The body weight of infected mice was monitored for 15 days. Blood
was collected at days 1–3 (BALB/c mice) or 1, 3, and 5 (A129 mice) post infection
for determination of viral RNA in sera by RT-qPCR. Testis and spleens were
collected at day 3 or day 7 post infection, to detect viral load by RT-qPCR.
For neurovirulence tests, 1-day-old suckling BALB/c mice were inoculated i.c.
with 10 PFU of ChinZIKV, YFV 17D, or JEV SA14-14-2, respectively. Animals
were monitored for 21 days after inoculation. Virus doses inducing a 50% mortality
rate were calculated using the method of Reed and Muench67.
To test whether persistent infection of ChinZIKV occurred in mice,
6-week-old male A129 mice were infected s.c. with 103 PFU of the chimera.
Multiple organs were collected for viral RNA detection on days 6 and 15 post
infection.
Immunogenicity was assessed by inoculation s.c. with 104 PFU of ChinZIKV
diluted in DMEM plus 2% FBS into 4-week-old female BALB/c mice. The mice
were bled by tail vein puncture 1 day before (Day 0) and at 4 weeks post
immunization. The sera were stored at − 20 °C for the determination of IgG by
ELISA and neutralizing antibodies by PRNT50. For the efﬁcacy assay, immunized
mice were challenged i.p. with 103 PFU of ZIKV strain GZ01 at 4 weeks post
immunization. Blood and testis were collected as described above for
determination of viral load in sera or the tested tissues, respectively.
For viral protection tests in pregnant mice and their offspring, 4-week-old
female BALB/c mice were immunized with 104 PFU of ChinZIKV or PBS. On day
60 post immunization, the immunized mice were mated to 10-week-old male
BALB/c mice. At embryonic day 13.5 (E13.5), the pregnant mice were infected with
105 PFU of ZIKV by the i.p. route. Viral RNA loads at days 1–3 post infection were
determined by RT-qPCR. One-day-old suckling mice born to immunized dams
were challenged i.c. with 100 PFU of ZIKV. The mice were then monitored for
clinical symptoms and mortality for 21 days.
The vertical transmission model of ZIKV was recently described15,47. Brieﬂy,
4-week-old female BALB/c mice were inoculated s.c. with 104 PFU of ChinZIKV or
PBS. On day 210 post immunization, immunized female mice were mated with
naive 10-week-old male BALB/c mice. At E5, pregnant dams were injected i.p. with
2 mg of mouse anti-Ifnar1 antibody (clone MAR1-5A3; Leinco Technologies,
USA). On E6, mice were challenged s.c. with 105 PFU of ZIKV. Viral RNA loads in
serum at days 1–3 post-challenge were determined by RT-qPCR. A set of animals
were killed on E13 and analyzed for viral loads in placentas, fetuses, and maternal
tissues as indicated. One of the PBS-immunized animals was killed on E18 to test
the outcome of fetuses. One of the ChinZIKV-immunized dams was observed until
delivery of pups at term.
Monkey experiments. All experimental procedures involving rhesus monkeys
were performed under sodium pentobarbital anesthesia by trained technicians and
all efforts were made to ameliorate the welfare and to minimize animal suffering in
accordance with the recommendations in The Use of Non-Human Primates in
Research.
For immunization and challenge of rhesus monkeys, a total of 11 adult rhesus
monkeys (weighing 4.5–6.0 kg) in good health were prescreened as negative for IgG
antibodies against ﬂaviviruses (including ZIKV, DENV, JEV, and YFV) by ELISA
assay. Detailed information is provided in Supplementary Table 3. All the animals
were housed individually in a single cage in a pathogen-free facility and
acclimatized for a week. Rhesus monkeys were inoculated s.c. with 0.5 ml of viral
solution containing 105 PFU (n = 5) of ChinZIKV or ZIKV (n = 3), or were sham
inoculated with PBS (n = 3). After the inoculation, clinical signs were recorded
during a 10-day observation period. Blood and major body ﬂuids were collected for
the determination of viral load. Blood was collected daily for 10 days to detect
viremia. Blood samples for neutralizing-antibody tests were taken before
immunization (day 0) and then on day 28 post immunization. On day 55 post
immunization, three of the animals were immunized with 105 PFU of ChinZIKV
and the PBS controls challenged by inoculation s.c. with 103 PFU of the ZIKV
strain GZ01. For the following 10 days, blood was collected for the determination
of viremia. Neutralizing antibody levels in serum were measured by PRNT50 as
described above.
Urine was collected from a container under the animal’s cage and was stored at
− 80 °C until analysis. Saliva was obtained by running a sterile swab under the
animal’s tongue. Swabs were placed immediately into 1.0 ml of viral transport
medium (tissue culture medium 199 supplemented with 0.5% FBS and 1%
antibiotic/antimycotic) for 60 min. Samples were vortexed vigorously, then
centrifuged for 10 min at 1,000 × g before removing the swabs. Samples were stored
at − 80 °C until processing.
Viral RNA was extracted from 0.1 ml of serum or 0.2 ml of urine and saliva
samples using a PureLink RNA minikit (Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions. RNA was eluted in 60 μl of RNase-free water,
aliquoted, and stored at − 80 °C until use.
Thoracic inoculation of mosquitoes. Detailed procedures for microinjection in
mosquitoes have been described previously68. In brief, female A. aegypti mosqui-
toes (Rockefeller strain) were anesthetized on a cold tray, and subsequently a
certain titre (0.2 PFU) of ZIKV or ChinZIKV was microinjected into the mosquito
thoraxes.
Viral RNA quantiﬁcation in animal serum and tissues by RT-qPCR. The
determination of viral RNA amounts by RT-qPCR was performed as described
previously35,69. Brieﬂy, the XhoI-linearized plasmids containing the full-length
genomic cDNA clones of ChinZIKV or ZIKV were subjected to in vitro tran-
scription using the RiboMAX Large Scale RNA Production System (Promega). The
resulting RNA transcripts were puriﬁed using a PureLink RNA minikit (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instructions and quantiﬁed using
spectrophotometry on Nanodrop 2000. The puriﬁed RNA was diluted 10-fold
serially using RNase-free water and was detected using RT-qPCR. Threshold cycle
(Ct) values for the known concentrations of the RNA were plotted against the log
of the number of genome equivalent copies. The resultant standard curve was used
to determine the number of genome equivalents of viral RNA in samples. The
determination of the detection limit was based on the lowest level at which viral
RNA was detected and remained within the range of linearity of a standard curve
(Ct value of 38.5). RT-qPCR was performed using One Step PrimeScript RT-PCR
Kit (Takara, Japan) with the primers and probes described in Supplementary
Table 2. The 20 μl reaction mixtures were set up with 2 μl of RNA. Cycling con-
ditions were as follows: 42 °C for 5 min, 95 °C for 10 s, followed by 40 cycles of 95 °
C for 5 s and 60 °C for 20 s.
Determination of viral load in mosquitoes by RT-qPCR. Total RNA was isolated
from homogenized mosquitoes using an RNeasy Mini Kit (Qiagen, Germany) and
reverse-transcribed into cDNA using an iScript cDNA synthesis kit (Bio-Rad,
USA). Viral genomes were quantiﬁed via RT-qPCR ampliﬁcation of ZIKV genes,
normalized against A. aegypti actin (AAEL011197). The detection limit of ZIKV E/
Actin mRNA ratio is 0.001. The primers and probes used for this analysis are
shown in Supplementary Table 2.
Cytokine secretion assays. Plasma samples of infected monkeys collected at days
0 and 7 post infection were stored frozen until analysis for cytokine production.
Plasma concentrations of epidermal growth factor, eotaxin, ﬁbroblast growth fac-
tor-basic, G-GSF, granulocyte–macrophage colony-stimulating factor, hepatocyte
growth factor, IFN-γ, IL-1β, IL-1RA, IL-2, 4, 5, 6, 8, 10, 12, 15, 17, IP-10, I-TAC,
MCP-1, MDC, MIF, MIG, MIP-1α, MIP-1β, RANTES, tumor necrosis factor-α,
and vascular endothelial growth factor were measured with a Monkey Cytokine
Magnetic 29-Plex Panel kit (Thermo Fisher Scientiﬁc) according to the manu-
facturer’s instruction. Antibody-coated magnetic microspheres optimized for
quantifying non-human primate speciﬁc cytokines were premixed and the multi-
plexed assay was performed according the manufacturer’s instructions. Cytokine
capture was performed overnight at 4 °C. Biotinylated cytokine detection anti-
bodies and streptavidin–phycoerythrin (Thermo Fisher Scientiﬁc) were used at the
manufacturer’s recommended dilution. Assays were performed on a Luminex
200™ machine equipped with Bio-Plex Manager Software (version 5.0) (Bio-Rad).
The heatmap was produced using a web-based tool Morpheus and the original data
were provided in Supplementary Tables 4 and 5.
Statistical analysis. For viral burden analysis, an unpaired two-tailed t test was
used to determine statistically signiﬁcant differences. For three groups, variation
between groups was measured by two-way analysis of variance with a multiple
comparison testing. For survival analysis, Kaplan–Meier survival curves were
analyzed by a log rank test. Statistical analyses were performed by using standard
GraphPad Prism software, version 5.0.
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